Recent news of emails released to the public from Dr. Anthony Fauci has caused the public to reconsider what they accepted from him as medical science, including the cure and treatment of COVID 19.
“Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients,” wrote Dr. Liji Thomas in an article published on Thursday.
The report comes out at the same time Fauci is under scrutiny for bad medical advice about the same medicine, which he was very negative about.
Breitbart reported that Fauci ignored recommendations for the drug.
Anthony Fauci Ignored Email from Physicist Claiming Hydroxychloroquine Could Help Battle Coronavirus https://t.co/oqSp7mKqVQ
— Jean Badgett (@jeanbadgett63) June 3, 2021
Now there is a comprehensive study that shows his misdeed.
A preprint is a version of a scholarly or scientific paper that precedes formal peer review and publication in a peer-reviewed scholarly or scientific journal.
Dr. Liji Thomas authored an article covering a preprint of medical tests which show compelling information about the use of a drug that the opponents of President Donald J. Trump made controversial for some unknown reason.
This is a partial Transcript of Thomas’ medical article on the preprint follows. Full article here.
Treatment options have been limited in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Earlier optimism regarding immunomodulatory drugs such as azithromycin (AZM) and hydroxychloroquine (HCQ) seemed to be undermined by results of large interventional trials.
However, a fascinating new study posted to the medRxiv* preprint server (not peer-reviewed*), suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
Using computational modeling, the use of weight-adjusted HCQ and AZM appears to be associated with a more than 100% reduction in mortality, without a clear correlation with ECG abnormalities.
In this study, based on a subset of critically ill COVID-19 patients, consisting of patients who required intubation and IMV, data from the medical records were analyzed using several novel methods. This included not only the vital signs and laboratory values but the therapeutic methods.
The study was carried out on patients at Saint Barnabas Medical Center, New Jersey, with just over 1% having been clinically diagnosed to have COVID-19. Of the 255 patients, almost 80% died during the study period. Seven patients were transferred to another hospital on the ventilator, mostly after day 40 of hospitalization.
The chief therapeutic classes included steroids, tocilizumab, convalescent plasma, hydroxychloroquine, and azithromycin.
VIDEO OF THE DAYFacebook Finally Loses
With every log increase in the cumulative dose of HCQ, the mortality rate fell by 1.12 times, such that at 3 g HCQ, survival odds rose by 2.5 times.
When given together with AZM, the benefit was still more significant. Chances of survival increased further. Among those who received both > 3g HCQ and >1g AZM, almost half survived, compared to one in seven (16%) among patients who received one of these drugs at the same dosages.
This means a 32% absolute difference in survival, or a relative improvement in survival odds of 200%, with the combination of HCQ/AZM at this dosage. This far exceeds the survival benefit cited in any study of any intervention so far.
When HCQ/AZM was given at lower dosages, the risk of death was over three times higher relative to the above combination and dosage regimen.